Anti‐PD‐1 antibody (SCT‐I10A) plus anti‐EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open‐label, phase 1b clinical trial
SCT-I10A plus SCT200 demonstrated durable antitumor activity with a manageable safety profile in previously treated patients with advanced ESCC, even in patients who had previously failed anti-PD-(L)1 therapy.
Authors
- Lin Shen (ORCID: https://orcid.org/0000-0001-8101-4129)
- Yi Ba
- Bing Xia (ORCID: https://orcid.org/0000-0002-1637-7908)
- Shegan Gao (ORCID: https://orcid.org/0000-0001-9055-1479)
- Zhen Zhang (ORCID: https://orcid.org/0000-0001-6286-8049)
- Ming Bai (ORCID: https://orcid.org/0000-0003-1863-9577)
- Yao Lu (ORCID: https://orcid.org/0000-0001-7539-5308)
- Zhichao Fu (ORCID: https://orcid.org/0000-0003-0341-106X)
- Liangzhi Xie (ORCID: https://orcid.org/0000-0002-8372-1393)
- Xianli Yin (ORCID: https://orcid.org/0000-0003-0746-5321)
Institutions
- Central South University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Peking Union Medical College Hospital (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Peking University Cancer Hospital (CN)
- Zhejiang Cancer Hospital (CN)
- Sinocelltech Group (China) (CN)
- Nanyang Institute of Technology (CN)
- Hunan Cancer Hospital (CN)
- First Affiliated Hospital of Henan University of Science and Technology (CN)
- The First People's Hospital of Guiyang (CN)
- Pingjin Hospital (CN)
- Hangzhou Cancer Hospital (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Cancer
- Published
- 2025-08-15
- DOI
- https://doi.org/10.1002/cncr.70046
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Major Science and Technology Projects of China